NAMSNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NAMSW

NewAmsterdam Pharma Co N.V.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$20.47+0.64 (+3.23%)

Close on Oct 19, 2026

Market cap: $2.53B
P/E (TTM): –
Dividend yield: –

NewAmsterdam Pharma Co N.V. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Cash & Equivalents	490	772	340	468	–	–	–
Short-Term Investments	146	62	–	–	–	–	–
Cash & Short-Term Investments	636	834	340	468	–	–	–
Prepaid Expenses & Other	38	24	6.34	10	–	–	–
Total Current Assets	676	863	347	478	–	–	–
Property, Plant & Equipment	0.38	0.24	0.05	0.03	–	–	–
Long-Term Investments	93	–	–	–	–	–	–
Operating Lease Right-of-Use Assets	0.19	0.43	0.06	0.12	–	–	–
Deferred Tax Assets	–	–	–	0	–	–	–
Total Assets	769	865	347	478	–	–	–
Accounts Payable	8.97	4.74	17	12	–	–	–
Current Portion of Leases	0.14	0.25	0.06	0.07	–	–	–
Deferred Revenue (Current)	3.99	6.01	8.94	14	–	–	–
Total Current Liabilities	86	107	50	36	–	–	–
Long-Term Leases	0.07	0.20	–	0.06	–	–	–
Operating Lease Liabilities	0.20	0.45	0.06	0.13	–	–	–
Total Liabilities	86	107	59	48	–	–	–
Common Stock	14	13	10	10	–	–	–
Additional Paid-In Capital	1,427	1,298	591	556	–	–	–
Retained Earnings	-762	-559	-317	-140	–	–	–
Comprehensive Income & Other	4.79	4.47	4.42	4.42	–	–	–
Shareholders' Equity	683	758	288	430	-114	-73	–
Total Equity	683	758	288	430	-114	-73	–
Total Liabilities & Equity	769	865	347	478	–	–	–
Shares Outstanding(shares)	114	108	82	82	11	5.00	2.50

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -3432.2%
Net margin: -3644.2%
Return on equity, FY2025: -28.3%

Financial strength

Current ratio: 9.03
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 581.2%

Valuation

P/E ratio: –
Price to sales: 354.64
Price to book: 4.00
Dividend yield: –